Consensus CSL Limited

Stocks

CSL

AU000000CSL8

Pharmaceuticals

Delayed Australian S.E. 02:33:15 16/10/2026 BST			5-day change	1st Jan Change
190.52 ^AUD	+1.93%		+3.62%	+10.33%

10-14	EU Accepts Sanofi's Concessions to End Antitrust Probe Over Vaccine Marketing -- Update	DJ
10-14	EU Accepts Sanofi's Concessions to Settle Antitrust Probe Over Vaccine Marketing	DJ

Evolution of the Average Target: CSL Limited

Evolution of the Target Price: CSL Limited

Changes in Analyst Recommendations: CSL Limited

96cc8fc00598bd5d69152af2b786.O428yMi3nbKHG1gpLlEa2b1onc5_j95RF-e2776Y24g.DMzOoKn664DzLB9kfDd_l-ku5Io43Ywbc7eGvY_akOFi-M3x8Mfz1eEqbA~ea147ead6ba646d3df488f25865dea30

Analysts' recommendations: CSL Limited

10-07	CSL's Alentis Licensing Deal Low-Risk, Low-Reward, RBC Capital Markets Says	MT
10-06	CSL's Alentis Licensing Deal Likely to Lead to Total Addressable Market of Up to Nearly $2 Billion per Year, Jefferies Says	MT
08-18	CSL's Fiscal 2026 Results In Line, Jefferies Says	MT
06-25	CSL, Plasma Industry Could Continue to Grow Strongly for Considerable Period, Jefferies Says	MT
05-12	CSL's Fiscal-Year Earnings Guidance Downgrade Not Surprising, Jefferies Says	MT
03-20	CSL's Business Not Threatened by CIDP Therapy Competition, Says Jefferies	MT
03-02	Organic Growth in Australia's Healthcare Services Likely Due to Increased Availability of Bulk-Billing General Practitioners, Jefferies Says	MT
02-11	CSL's Fiscal H1 EBIT Boosted by Cost Reductions, Jarden Says	MT
12-08	CSL's China Albumin Sale to Improve in Fiscal H2 2026, Says Jefferies	MT
11-11	CSL Impacted by Launch Delays, Vaccine Fatigue, Says Jefferies	MT
11-07	CSL Expected to See Potential Medium-Term Earnings Upside, Says Jefferies	MT
11-07	CSL's Horizon 2 Approach to 'Significantly' Boost Margins, Earnings, Jarden Says	MT
29/10/25	Jarden Research Adjusts CSL's Price Target to AU$287.14 from AU$304.17, Keeps at Overweight	MT
29/10/25	CSL Faces Macroeconomic Challenges, Will Take Time to Rerate, Says Jefferies, Shares Down 3%	MT
28/10/25	Canaccord Genuity Upgrades CSL to Buy from Hold; Price Target is AU$225	MT
28/10/25	CSL's Flu Revenue Impact for Northern Hemisphere Season Drives Guidance Downgrade, Jarden Says	MT
02/10/25	CSL to Benefit From Immunoglobin Sales Growth, Says Jefferies	MT
31/07/25	Carlisle Faces Downgrade From Loop Capital; Shares Fall	MT
11/07/25	CSL Shares Fall Amid Target Price Cut by Morgans Financial	MT
10/07/25	Morgans Financial Upgrades CSL to Buy from Add; Price Target is AU$303.70	MT
25/10/24	CSL's R&D Day "Uninspiring," Jarden Research Says	MT
09/09/24	CSL 'Strong Franchise in Medium Term' Amid Higher Fiscal 2024 Earnings, Jefferies Says	MT
04/09/24	Carlisle Expected to Show Solid Growth, Margin Expansion, Oppenheimer Says	MT
14/08/24	Jarden Research Adjusts CSL's Price Target to AU$329.62 From AU$305.34, Keeps at Overweight	MT
06/03/24	Morgan Stanley Adjusts CSL’s Price Target to AU$310 From AU$318, Keeps at Overweight	MT